Overview

Study of T-DXd Monotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

Status:
Recruiting

Trial end date:
2023-08-31

Target enrollment:

Participant gender:

Summary

This is a Phase II, open-label, single-arm, multicentre, study in China assessing the efficacy and safety of T-DXd in participants with HER2-positive advanced gastric or GEJ adenocarcinoma who have received at least 2 prior regimens including a fluoropyrimidine agent and a platinum agent

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Daiichi Sankyo Co., Ltd.

Treatments:

Trastuzumab